Skip Nav Destination
Issues
1 December 2008
-
Cover Image
Cover Image
MicroCT images depicting orthotopic lung tumor xenografts growing in mice treated with vehicle control (top left); carboplatin/taxol chemotherapy (bottom left); the pro-apoptotic DR5 agonist antibody apomab (top right); and the combination of apomab plus carboplatin/taxol chemotherapy (bottom right). Apomab cooperates with chemotherapy to inhibit lung tumor growth. For further details, please see the report by Jin and colleagues on page 7733 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Human Cancer Biology
Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors
Raisa Vuononvirta; Neil J. Sebire; Anthony R. Dallosso; Jorge S. Reis-Filho; Richard D. Williams; Alan Mackay; Kerry Fenwick; Anita Grigoriadis; Alan Ashworth; Kathy Pritchard-Jones; Keith W. Brown; Gordan M. Vujanic; Chris Jones
Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer
Michael J. Callahan; Zoltan Nagymanyoki; Tomas Bonome; Michael E. Johnson; Babak Litkouhi; Elizabeth H. Sullivan; Michelle S. Hirsch; Ursula A. Matulonis; Joyce Liu; Michael J. Birrer; Ross S. Berkowitz; Samuel C. Mok
Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting
Priya Koppikar; Vivian Wai Yan Lui; David Man; Sichuan Xi; Raymond Liu Chai; Elizabeth Nelson; Allison B.J. Tobey; Jennifer Rubin Grandis
Cancer Therapy: Preclinical
Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor α–Mediated Ceramide De novo Synthesis in Colon Cancer Cells
Fabio Cianchi; Laura Papucci; Nicola Schiavone; Matteo Lulli; Lucia Magnelli; Maria Cristina Vinci; Luca Messerini; Clementina Manera; Elisa Ronconi; Paola Romagnani; Martino Donnini; Giuliano Perigli; Giacomo Trallori; Elisabetta Tanganelli; Sergio Capaccioli; Emanuela Masini
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Seiji Mabuchi; Yoshito Terai; Kenichiro Morishige; Akiko Tanabe-Kimura; Hiroshi Sasaki; Masanori Kanemura; Satoshi Tsunetoh; Yoshimichi Tanaka; Masahiro Sakata; Robert A. Burger; Tadashi Kimura; Masahide Ohmichi
Imaging, Diagnosis, Prognosis
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer
Stefan Holdenrieder; Joachim von Pawel; Elke Dankelmann; Thomas Duell; Bernhard Faderl; Andreas Markus; Maria Siakavara; Horst Wagner; Knut Feldmann; Harald Hoffmann; Hannelore Raith; Dorothea Nagel; Petra Stieber
Heat Shock Protein 90 Overexpression Independently Predicts Inferior Disease-Free Survival with Differential Expression of the α and β Isoforms in Gastrointestinal Stromal Tumors
Chien-Feng Li; Wen-Wei Huang; Jing-Mei Wu; Shih-Chen Yu; Tsung-Hui Hu; Yih-Huei Uen; Yu-Fang Tian; Ching-Nan Lin; David Lu; Fu-Min Fang; Hsuan-Ying Huang
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients
Achim Fleischmann; Thorsten Schlomm; Hartwig Huland; Jens Köllermann; Philipp Simon; Martina Mirlacher; Georg Salomon; Felix H.K. Chun; Thomas Steuber; Ronald Simon; Guido Sauter; Markus Graefen; Andreas Erbersdobler
Cancer Therapy: Clinical
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Michael F. Press; Richard S. Finn; David Cameron; Angelo Di Leo; Charles E. Geyer; Ivonne E. Villalobos; Angela Santiago; Roberta Guzman; Armen Gasparyan; Yanling Ma; Kathy Danenberg; Anne Marie Martin; Lisa Williams; Cristina Oliva; Steven Stein; Robert Gagnon; Michael Arbushites; Maria T. Koehler
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Harold J. Burstein; Yu-Hui Chen; Leroy M. Parker; Jennifer Savoie; Jerry Younger; Irene Kuter; Paula D. Ryan; Judy E. Garber; Helen Chen; Susana M. Campos; Lawrence N. Shulman; Lyndsay N. Harris; Rebecca Gelman; Eric P. Winer
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Maura N. Dickler; Hope S. Rugo; Carey A. Eberle; Edi Brogi; James F. Caravelli; Katherine S. Panageas; Jeff Boyd; Benjamin Yeh; Diana E. Lake; Chau T. Dang; Teresa A. Gilewski; Jacqueline F. Bromberg; Andrew D. Seidman; Gabriella M. D'Andrea; Mark M. Moasser; Michele Melisko; John W. Park; Janet Dancey; Larry Norton; Clifford A. Hudis
Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
Georg Lurje; Fumio Nagashima; Wu Zhang; Dongyun Yang; Heung M. Chang; Michael A. Gordon; Anthony El-Khoueiry; Hatim Husain; Peter M. Wilson; Robert D. Ladner; David J. Mauro; Christiane Langer; Eric K. Rowinsky; Heinz-Josef Lenz
FAS Promoter Polymorphism: Outcome of Childhood Acute Myeloid Leukemia. A Children's Oncology Group Report
Parinda A. Mehta; Robert B. Gerbing; Todd A. Alonzo; James S. Elliott; Tiffany A. Zamzow; Michelle Combs; Emily Stover; Julie A. Ross; John P. Perentesis; Soheil Meschinchi; Beverly J. Lange; Stella M. Davies
Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
Julian R. Molina; Scott H. Kaufmann; Joel M. Reid; Stephen D. Rubin; Marina Gálvez-Peralta; Robert Friedman; Karen S. Flatten; Kevin M. Koch; Tona M. Gilmer; Robert J. Mullin; Roxanne C. Jewell; Sara J. Felten; Sumithra Mandrekar; Alex A. Adjei; Charles Erlichman
Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
Stacy L. Moulder; W. Fraser Symmans; Daniel J. Booser; Timothy L. Madden; Cindy Lipsanen; Linda Yuan; Abenaa M. Brewster; Massimo Cristofanilli; Kelly K. Hunt; Thomas A. Buchholz; James Zwiebel; Vicente Valero; Gabriel N. Hortobagyi; Francisco J. Esteva
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function
Marco Siano; Erika Lerch; Laura Negretti; Emanuele Zucca; Delvys Rodriguez-Abreu; Michel Oberson; Leda Leoncini; Oreste Mora; Cristiana Sessa; Augusto Gallino; Michele Ghielmini
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath; David W. Hillman; Ulka Vaishampayan; Shijie Sheng; Fazlul Sarkar; Felicity Harper; Melvin Gaskins; Henry C. Pitot; Winston Tan; S. Percy Ivy; Roberto Pili; Michael A. Carducci; Charles Erlichman; Glenn Liu
Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors
Alejandro D. Ricart; Jordan D. Berlin; Kyriakos P. Papadopoulos; Samira Syed; Daniel W. Drolet; Charlotte Quaratino-Baker; Julie Horan; Jon Chick; Wendy Vermeulen; Anthony W. Tolcher; Eric K. Rowinsky; Mace L. Rothenberg
Cancer Prevention and Susceptibility
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds